Recent events
Recent events tied to this brand in public sources.
Back to profile27 entries · Page 2 of 2
2020
FDA approves Epclusa for pediatric HCV treatment
The FDA approved Epclusa for children aged 6 years and older or weighing at least 37 pounds to treat hepatitis C virus; the article reports that the medicine is available for children with any of the six HCV genotypes.
2020
Gilead Sciences announces agreement to acquire Forty Seven
Gilead Sciences and Forty Seven announced a definitive agreement under which a Gilead subsidiary will acquire all outstanding common shares of Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. Completion was expected during the second quarter of 2020, subject to regulatory approval and other transaction details.
2020
Gilead agrees to support remdesivir clinical trials in China
Gilead said it had reached an agreement with Chinese health authorities to support two clinical trials of remdesivir in people infected with 2019-nCoV. The trials were led by Chinese researchers and conducted in Wuhan.
2020
Gilead responds to questions about remdesivir trials and patents
Gilead issued a statement addressing questions about remdesivir, saying it had reached an agreement with Chinese health authorities to support two clinical trials and that it holds patents for the drug in China, the United States and elsewhere. It also said the China patent application for coronavirus use was pending approval.
2019
U.S. government sues Gilead over PrEP patent rights
The U.S. Department of Health and Human Services sued Gilead Sciences over patent rights to Truvada and Descovy for HIV prevention. The lawsuit alleges that the government owns the PrEP patents; those claims are allegations, not a court determination.
2019
Gilead Sciences announces Andrew Dickinson as CFO
Gilead Sciences announced that Andrew Dickinson had been appointed Chief Financial Officer, effective November 1.
2019
FDA approves Descovy for HIV prevention
The FDA approved Gilead Sciences’ Descovy for marketing as a pre-exposure prophylaxis medication to prevent HIV.